This research demonstrates sensitive detection of IRF5 subgroups in systemic lupus erythematosus, suggesting implications for precision medicine.
The SP-PLA enabled sensitive and specific detection of low-level IRF5 in plasma and confirmed the presence of IRF5 high and low subgroups in SLE using a quantitative method. These findings support the potential of IRF5 as a biomarker, but validation in independent cohorts is required. The assay may facilitate patient stratification in future research and precision medicine approaches targeting the interferon pathway.
No takes yet. Share an insight, caveat, or question.
Karami et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: